Results 21 to 30 of about 154,650 (346)

Nonalcoholic Steatohepatitis [PDF]

open access: yesMayo Clinic Proceedings, 2000
Nonalcoholic steatohepatitis (NASH) is a liver disease that, until recently, has been underrecognized as a common cause of elevated liver enzymes. This distinct clinical entity is characterized by liver biopsy findings similar to those seen in alcoholic hepatitis but in the absence of alcohol consumption sufficient to cause such changes.
K S, Kumar, P F, Malet
openaire   +2 more sources

A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies

open access: yesCells, 2021
5′AMP-activated protein kinase (AMPK) is known as metabolic sensor in mammalian cells that becomes activated by an increasing adenosine monophosphate (AMP)/adenosine triphosphate (ATP) ratio. The heterotrimeric AMPK protein comprises three subunits, each
Christian von Loeffelholz   +2 more
doaj   +1 more source

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

open access: yesNew England Journal of Medicine, 2020
BACKGROUND Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited.
P. Newsome   +8 more
semanticscholar   +1 more source

Efficacy and Safety of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycholic Acid Combination in Chronic Hepatitis Related to Metabolic Syndrome Components

open access: yesThe Korean Journal of Gastroenterology, 2021
Backgrounds/Aims: Steatohepatitis related to metabolic syndrome is a chronic liver disease prevalent in patients not only with non-alcoholic steatohepatitis but also with alcoholic liver disease and chronic viral hepatitis.
Nae-Yun Heo   +10 more
doaj   +1 more source

Iron and steatohepatitis [PDF]

open access: yesJournal of Gastroenterology and Hepatology, 2012
AbstractAs the main iron storage site in the body and the main source of the iron‐regulatory hormone, hepcidin, the liver plays a pivotal role in iron homeostasis. A variable degree of hepatic iron accumulation has long been recognized in a number of chronic liver diseases.
CORRADINI, Elena, PIETRANGELO, Antonello
openaire   +2 more sources

Immune cell-mediated features of non-alcoholic steatohepatitis

open access: yesNature reviews. Immunology, 2021
Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations, starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis (NASH), cirrhosis or even hepatocellular carcinoma. NAFLD is a major health
T. Huby, E. Gautier
semanticscholar   +1 more source

Role of Leptin in Non-Alcoholic Fatty Liver Disease

open access: yesBiomedicines, 2021
Non-alcoholic fatty liver disease (NAFLD), which affects about a quarter of the global population, poses a substantial health and economic burden in all countries, yet there is no approved pharmacotherapy to treat this entity, nor well-established ...
Carlos Jiménez-Cortegana   +7 more
doaj   +1 more source

Distinct Influence of Hypercaloric Diets Predominant with Fat or Fat and Sucrose on Adipose Tissue and Liver Inflammation in Mice

open access: yesMolecules, 2020
Overfeeding of a hypercaloric diet leads to obesity, diabetes, chronic inflammation, and fatty liver disease. Although limiting fat or carbohydrate intake is the cornerstone for obesity management, whether lowering fat or reducing carbohydrate intake is ...
Caíque S. M. Fonseca   +6 more
doaj   +1 more source

Beneficial Effects of Opuntia spp. on Liver Health

open access: yesAntioxidants, 2023
The genus Opuntia spp. includes plants capable of growing in arid, temperate and tropical climates. The vast majority of wild species grow in Mexico, but O.
Irene Besné-Eseverri   +5 more
doaj   +1 more source

Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study.

open access: yesClinical Gastroenterology and Hepatology, 2023
BACKGROUND & AIMS Cenicriviroc (CVC) is a novel, orally administered, chemokine receptor type 2 and 5 antagonist that showed antifibrotic potential in preclinical and phase IIb studies of nonalcoholic steatohepatitis (NASH).
Q. Anstee   +10 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy